GMAB.CO
Price:
$1765
Market Cap:
$112.09B
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating sol...[Read more]
Industry
Biotechnology
IPO Date
2000-10-20
Stock Exchange
CPH
Ticker
GMAB.CO
According to Genmab A/S’s latest financial reports and current stock price. The company's current ROE is 17.44%. This represents a change of 298.84% compared to the average of 4.37% of the last 4 quarters.
The mean historical ROE of Genmab A/S over the last ten years is 18.45%. The current 17.44% ROE has changed -5.49% with respect to the historical average. Over the past ten years (40 quarters), GMAB.CO's ROE was at its highest in in the June 2020 quarter at 18.90%. The ROE was at its lowest in in the March 2016 quarter at -0.33%.
Average
18.45%
Median
17.98%
Minimum
13.32%
Maximum
24.88%
Discovering the peaks and valleys of Genmab A/S ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 61.39%
Maximum Annual ROE = 24.88%
Minimum Annual Increase = -46.46%
Minimum Annual ROE = 13.32%
Year | ROE | Change |
---|---|---|
2023 | 13.77% | -30.70% |
2022 | 19.87% | 49.13% |
2021 | 13.32% | -46.46% |
2020 | 24.88% | 61.39% |
2019 | 15.42% | -16.06% |
2018 | 18.37% | 4.40% |
2017 | 17.59% | -28.46% |
2016 | 24.59% | 12.31% |
2015 | 21.90% | 47.75% |
2014 | 14.82% | 39.33% |
The current ROE of Genmab A/S (GMAB.CO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.65%
5-year avg
17.45%
10-year avg
18.45%
Genmab A/S’s ROE is less than Ambu A/S (8.12%), less than DSV A/S (15.46%), less than Bavarian Nordic A/S (7.02%), less than GN Store Nord A/S (6.08%), less than FLSmidth & Co. A/S (6.05%),
Company | ROE | Market cap |
---|---|---|
8.12% | $35.99B | |
15.46% | $286.39B | |
7.02% | $19.36B | |
6.08% | $23.73B | |
6.05% | $19.59B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genmab A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genmab A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Genmab A/S's ROE?
How is the ROE calculated for Genmab A/S (GMAB.CO)?
What is the highest ROE for Genmab A/S (GMAB.CO)?
What is the 3-year average ROE for Genmab A/S (GMAB.CO)?
What is the 5-year average ROE for Genmab A/S (GMAB.CO)?
How does the current ROE for Genmab A/S (GMAB.CO) compare to its historical average?